BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Identifying Significant Trends in Plant Therapy

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is working with researchers to provide a full turnkey solution for clinical studies from start to finish. “As research restrictions throughout the U.S. lift, RYAH Group is standing by, ready to provide IoT hardware, software and data analytics that reduce variations in patient-related clinical trials. One of the areas that the U.S. is poised to explore is cannabis in sports medicine,” reads a recent article. Sports organizations must rethink their strict policies with the legalization of recreational and medicinal cannabis across the country. The good news is that new studies around plant therapy in sports medicine, a new era of pain management and recovery accepted by sports organizations worldwide, may lie right around the corner for athletes. “RYAH Group is working alongside researchers globally, providing a holistic approach to therapeutic plant treatment and unlocking the data from seed to consumption. The company’s in-depth analytical reports help to identify significant trends, like the one in sports medicine, in plant therapy.”

To view the full article, visit https://ibn.fm/YgzSx

About RYAH Group Inc.

RYAH is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries, pharmaceutical companies, and licensed processors (“LPs”) to monitor and manage formulation effects on patients and demographics. With a strong intellectual property portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle. For more information about the company, visit www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH 

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Submits IND Amendment for Planned Phase 2a Trial of TTX-MC138 in Colorectal Cancer

TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of an Investigational New Drug ("IND") application amendment…

1 day ago

BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports New Cellular Data Demonstrating Coordinated Intracellular Zinc Increase and Iron Reduction With Telomir-Zn

Telomir Pharmaceuticals (NASDAQ: TELO) announced new cellular study results showing that Telomir-1, administered as Telomir-Zn,…

1 day ago

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Engages DUCK FLATS Pharma for IND Readiness and Regulatory Execution

Oragenics (NYSE American: OGEN) announced that it has engaged DUCK FLATS Pharma as its U.S.…

3 days ago

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Participates in SCOPE Summit 2026 Ahead of Phase 2a Concussion Trial

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing intranasal therapeutics for neurological disorders, announced…

4 days ago

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Mission Matters Podcast Interview With President Anil Diwan

NanoViricides, Inc. (NYSE American: NNVC) announced that President Dr. Anil R. Diwan was interviewed on…

4 days ago

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…

1 week ago